Literature DB >> 263836

Pathology of the heart in Kawasaki disease.

H Fujiwara, Y Hamashima.   

Abstract

Pathologic studies were done on 20 hearts of patients who had typical clinical signs and symptoms of Kawasaki disease. The cardiac lesions were classified according to the duration of illness at the time of death. Stage I (zero to nine days) was characterized by acute perivasculitis and vasculitis of the microvessels (arterioles, capillaries, and venules) and small arteries, and acute perivasculitis and endarteritis of the three major coronary arteries (MCAs). Pericarditis, myocarditis, inflammation of the atrioventricular conduction system, and endocarditis with valvulitis were also present. Stage II (12 to 25 days) was characterized by panvasculitis of the MCAs and aneurysm with thrombus in the stems. Myocarditis, coagulation necrosis, lesion of the conduction system, pericarditis, and endocarditis with valvulitis were also present. In stage III (28 to 31 days), granulation of the MCAs and disappearance of inflammation in the microvessels were noted. Patients in stage IV (40 days to 4 years) had scarring with severe stenosis in the MCAs. Fibrosis of the myocardium, coagulation necrosis, lesions of the conduction system, and endocardial fibroelastosis were also present. The features observed revealed Kawasaki disease to be acute and inflammatory. The angiitis begins in the microvessels and fibrinoid necrosis of the media is rare. The disease is one with a pathologic pattern previously unknown.

Entities:  

Mesh:

Year:  1978        PMID: 263836

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  103 in total

1.  Expression of IL-8 in Kawasaki disease.

Authors:  T Asano; S Ogawa
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  Myocardial ischemia in Kawasaki disease: evaluation with dipyridamole stress technetium 99m tetrofosmin scintigraphy.

Authors:  Tsuyoshi Fukuda; Masatoshi Ishibashi; Tatsuo Yokoyama; Masaki Otaki; Tohru Shinohara; Yoshihide Nakamura; Toshiharu Miyake; Takashi Kudoh; Hidetaka Oku
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

4.  Kawasaki disease in India.

Authors:  Bhagyavathy Bagyaraj; Usha Krishnan; Farida Farzana
Journal:  Indian J Pediatr       Date:  2003-11       Impact factor: 1.967

5.  Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease.

Authors:  E Tsuda; T Kamiya; Y Ono; K Kimura; K Kurosaki; S Echigo
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

6.  Th1 and Th2 cytokine production is suppressed at the level of transcriptional regulation in Kawasaki disease.

Authors:  J Kimura; H Takada; A Nomura; T Ohno; Y Mizuno; M Saito; K Kusuhara; T Hara
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  Anesthetic management of the patient with a history of Kawasaki disease--a report of 19 cases.

Authors:  Y Kojima; Y Kitahara; F Nozaki
Journal:  J Anesth       Date:  1990-04       Impact factor: 2.078

8.  Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease.

Authors:  Shuang Chen; Youngho Lee; Timothy R Crother; Michael Fishbein; Wenxuan Zhang; Atilla Yilmaz; Kenichi Shimada; Danica J Schulte; Thomas J A Lehman; Prediman K Shah; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

9.  Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease.

Authors:  Y F Cheung; M H K Ho; S C F Tam; T C Yung
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

10.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Authors:  M C Nash; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.